SCHEMBL1314851

SCHEMBL1314851

NC(=O)C=Cc1ccc(O)c(O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.69
MAPT P10636 3/20 0.69
TTR P02766 3/20 0.69
KMT2A Q03164 3/20 0.69
HSD17B10 Q99714 2/20 0.69
APP P05067 2/20 0.69
GAA P10253 2/20 0.69
PTPN1 P18031 2/20 0.69
MAPK1 P28482 2/20 0.69
MEN1 O00255 2/20 0.69
AKR1B1 P15121 2/20 0.69
NFKB1 P19838 2/20 0.69
DPP4 P27487 2/20 0.69
HDAC6 Q9UBN7 2/20 0.69
HDAC3 O15379 1/20 0.69
CA12 O43570 1/20 0.69
AKR1B10 O60218 1/20 0.69
ALDH1A1 P00352 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8916399 1.00 KDM4E (0.69) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL29773361 1.00 KDM4E (0.69) KDM4EMAPTTTRKMT2AHSD17B10
Phenol SCHEMBL28949254 0.90 MMP1 (0.62) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL2221673 0.83 KDM4E (0.74) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL5598948 0.83 KDM4E (0.74) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL30740005 0.83 PELI1 (0.53) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL30739974 0.83 PELI1 (0.53) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL21986709 0.83 PELI1 (0.53) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL30740008 0.83 PELI1 (0.53) KDM4EMAPTTTRKMT2AHSD17B10
SCHEMBL21986714 0.83 PELI1 (0.53) KDM4EMAPTTTRKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118919149-A Corrosion-resistant low-voltage cable and preparation method thereof 启源电气股份有限公司 2024-11-08 CN claimed
CN-118146694-A Epoxy pipeline paint for cast iron pipe and cast iron fitting for building drainage and preparation method thereof 江苏进华重防腐涂料有限公司 2024-06-07 CN claimed
EP-4228667-A1 METHODS FOR REVERSING HEPATIC STEATOSIS Brightseed, Inc. (US) 2023-08-23 EP claimed
CN-115536604-A Caffeic acid amide compound and application thereof 广西大学 2022-12-30 CN claimed
EP-4003060-A1 METHOD FOR IMPROVING DIGESTIVE HEALTH Brightseed, Inc. (US) 2022-06-01 EP claimed
WO-2022081567-A1 METHODS FOR REVERSING HEPATIC STEATOSIS BRIGHTSEED, INC. (US) 2022-04-21 WO claimed
CN-110643061-B Preparation method of formamide-free environment-friendly rubber and plastic foamed product 神州节能科技集团有限公司 2021-03-30 CN claimed
CN-112194691-A Method for preparing catalpol and catalpol derivative based on radix rehmanniae preparata and application of catalpol derivative 河北仁心药业有限公司 2021-01-08 CN claimed
CN-110643061-A Preparation method of formamide-free environment-friendly rubber and plastic foamed product 神州节能科技集团有限公司 2020-01-03 CN claimed
CN-104274433-B application of caffeic acid amide derivative 中国医药大学 2017-01-04 CN claimed
CN-104274433-A application of caffeic acid amide derivative UNIV CHINA MEDICAL 2015-01-14 CN claimed
US-8450337-B2 Methods of treating skin disorders with caffeic acid analogs MOLECULIN, LLC (US) 2013-05-28 US claimed
US-20100152143-A1 Methods of Treating Skin Disorders with Caffeic Acid Analogs MOLECULIN, LLC (US) 2010-06-17 US claimed
EP-0971743-B1 STABILIZED MEDICAMENTS CONTAINING CYSTEINYL DERIVATIVES STANISLAUS FRITZ (DE) 2006-07-12 EP claimed
US-20030119909-A1 Stabilized medicament containing cysteinyl derivatives STANISLAUS, FRITZ (DE) 2003-06-26 US claimed
US-20020037855-A1 Stabilized medicament containing cysteinyl derivatives STANISLAUS FRITZ (DE) 2002-03-28 US claimed
US-5686082-A AN ANTIOXIDIZING SYSTEM L'OREAL (FR) 1997-11-11 US claimed
JP-5058978-A None JP disclosed
JP-H02104568-A ACTING AGENT OF PRODUCTION PROMOTION OF NERVE GROWTH FACTOR YOSHITOMI PHARMACEUT IND LTD 1990-04-17 JP disclosed
JP-H00710739-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152143-A1 Methods of Treating Skin Disorders with Caffeic Acid Analogs CUTA, TYR, PPARA KDM4E 662/4885MAPT 784/4885TTR 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.